Reverse of NK cytolysis resistance of type II cytokine predominant-human tumor cells

International Immunopharmacology

Volumn 6, Issue 7, 2006, Pages 1176-1180

  Zhang, Jian ^a   Sun, Rui ^a   Liu, Jie ^a   Wang, Lei ^a   Tian, Zhigang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Cytokines; Cytotoxicity; Human tumor; Natural killer cells; Predominance

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; MONOCLONAL ANTIBODY; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOLYSIS; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; RNA, MESSENGER;

EID: 33747403373     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.02.011     Document Type: Article

References (15)

1. Paul W.E. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 77 (1991) 1859-1870
2. Zurawski G., and de Vries J.E. Interleukin 13 elicits a subset of the activities of its close relative interleukin 4. Stem Cells 12 2 (1994) 169-174
3. Moore K.W., de Waal Malefyt R., Coffman R.L., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19 (2001) 683-765
4. Luczynski W., Kovalchuk O., Krawczuk-Rybak M., Mitura-Lesiuk M., Malinowska I., Chyczewski L., et al. Lower expression of mRNA for interferon-gamma in T helper cells of children with newly diagnosed lymphomas. Folia Histochem Cytobiol 43 3 (2005) 169-171
5. Bais A.G., Beckmann I., Lindemans J., Ewing P.C., Meijer C.J., Snijders P.J., et al. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol 58 10 (2005) 1096-1100
6. Shibata M., Nezu T., Kanou H., Abe H., Takekawa M., and Fukuzawa M. Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol 34 4 (2002) 416-420
7. Sato M., Goto S., Kaneko R., Ito M., Sato S., and Takeuchi S. Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anticancer Res 18 5D (1998) 3951-3955
8. Mann E.A., Spiro J.D., Chen L.L., and Kreutzer D.L. Cytokine expression by head and neck squamous cell carcinomas. Am J Surg 164 6 (1992) 567-573
9. Huang M., Wang J., Lee P., Sharma S., Mao J.T., Meissner H., et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 55 17 (1995) 3847-3853
10. Boon T., Coulie P.G., and Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 18 (1997) 267-268
11. Herberman R.B., Nunn M.E., Holden H.T., and Lavrin D.H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 16 2 (1975) 230-239
12. Kessler D.J., Mickel R.A., and Lichtenstein A. Depressed natural killer cell activity in cervical lymph nodes containing focal metastatic squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 114 3 (1988) 313-318
13. Barker N., and Clevers H. Tumor environment: a potent driving force in colorectal cancer?. Trends Mol Med 7 12 (2001) 535-537
14. Oka H., Emori Y., Ohya O., Kobayashi N., Sasaki H., Tanaka Y., et al. An immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis, Z-100, restores the balance of Th1/Th2 cell responses in tumor bearing mice. Immunol Lett 70 2 (1999) 109-117
15. Yoshino S., Tabata T., Hazama S., Iizuka N., Yamamoto K., Hirayama M., et al. Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancers. Anticancer Res 20 6C (2000) 4707-4711